Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04745234 · ClinicalTrials.gov registry record · Phase 2
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
A Phase 2 study of Cutaneous T-Cell Lymphoma Refractory and Cutaneous T-Cell Lymphoma, Relapsed, sponsored by Kyowa Kirin.
- Active
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 16
- Study locations
NCT04745234: Active Phase 2 study of Cutaneous T-Cell Lymphoma Refractory and Cutaneous T-Cell Lymphoma, Relapsed, sponsored by Kyowa Kirin.
NCT04745234 is a Phase 2 study of Cutaneous T-Cell Lymphoma Refractory and Cutaneous T-Cell Lymphoma, Relapsed that is active but no longer recruiting, run by Kyowa Kirin. The registered enrollment target is 34 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower). The trial reports 16 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04745234, a Phase 2 study of Cutaneous T-Cell Lymphoma Refractory and Cutaneous T-Cell Lymphoma, Relapsed, is active but no longer recruiting, sponsored by Kyowa Kirin.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 16
- Study locations
Study Summary
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.
Conditions Studied
Interventions
- DRUG Mogamulizumab
Study Locations (16)
Other
- Hôpital Saint Louis - Paris
- Azienda Ospedaliera Città della Salute e della Scienza di Torino - Turin
- Hospital del Mar - Barcelona
- Hospital Universitario 12 de Octubre - Madrid
- Hospital Universitario Fundacion Jimenez Diaz - Madrid
- Hospital Universitario De Salamanca - Salamanca
- Queen Elizabeth Hospital - Birmingham
- Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital - London
- The Christie NHS Foundation Trust - Manchester
California
- City of Hope National Medical Center - Duarte
- University of California Irvine - Irvine
- Stanford Cancer Center - Stanford
Louisiana
- Tulane University School of Medicine - New Orleans
New York
- New York Presbyterian Hospital - New York
Pennsylvania
- University of Pittsburgh School of Medicine - Pittsburgh
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2021-08-16 |
| Est. Completion | 2025-05 |
| Phase | Phase 2 |
What the registry record for NCT04745234 still lists
NCT04745234 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Cutaneous T-Cell Lymphoma Refractory appearing as the primary indexed condition, and to 1 intervention - of which Mogamulizumab is the first listed.
NCT04745234 lists 16 locations in 6 states (Other, California, Louisiana).
Frequently Asked Questions
What is clinical trial NCT04745234 about?
NCT04745234 is a clinical study titled "Mogamulizumab Q4week Dosing in Participants With R/R CTCL". This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participa...
What is the current status of trial NCT04745234?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2021-08-16. Estimated completion is 2025-05.
What conditions does trial NCT04745234 study?
This clinical trial studies the following conditions: Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed.
What interventions are being tested in trial NCT04745234?
The interventions under investigation include: Mogamulizumab (DRUG).
Who is sponsoring clinical trial NCT04745234?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04745234 being conducted?
This trial has 16 study locations across California, Louisiana, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous T-Cell Lymphoma Refractory
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04745234's enrollment target sits among peer trials
34 1539th of 2000 higher than 448 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI